Psychometric Validation and Scale Derivation of the ICIQ‐Underactive Bladder Patient Reported Outcome Measure
Neurourology and Urodynamics · 2025-06 · 44 (5) · 1099-1108
DOI: 10.1002/nau.70065 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Neurourology and Urodynamics, online erschienen am 29.04.2025. Verfasst von Alan Uren und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Urological Institute, Southmead Hospital, Bristol, UK. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Urinary Bladder, Underactive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: This study was funded by Astellas Pharma Europe., Astellas Pharma Europe.
Abstract (Originalsprache)
Aims
To complete the psychometric validation and scale derivation of the International Consultation on Incontinence Questionnaire‐Underactive Bladder (ICIQ‐UAB).
Methods
The developmental ICIQ‐UAB was administered within a Phase II randomised controlled trial of a drug for the treatment of underactive bladder at baseline and follow‐up 4 weeks after the start of trial medication treatment. Descriptive analyses and exploratory factor analyses (EFAs) informed the derivation of scored domains for symptoms, health‐related quality of life (HRQoL), and associated bother items. The reliability was assessed by Cronbach's α, while validity was assessed via the correlation with other concurrently administered PROMs at baseline. Responsiveness was evaluated using the change in mean scores from baseline to follow‐up.
Results
A total of 132 male and female patients with the symptomatic and urodynamic characteristics of detrusor underactivity were enrolled in the analysis. Descriptive analyses and EFAs informed scored domains for 11 symptom items with associated bother, and 7 HRQoL items with associated bother. A further 8 unscored symptom items and one overall HRQL item were retained for their clinical utility. Sensitivity of the ICIQ‐UAB to the severity of the condition was supported (known groups validity), and correlations with concurrent PROMs were as expected, showing evidence of construct validity. All domains demonstrated reliability (Cronbach's α ≥ 0.88). Limited evidence for responsiveness was found, which was likely due to insufficient efficacy of trial medication treatment over administration time‐points.
Conclusions
The two scored domains and associated bother for the ICIQ‐UAB have been shown to be reliable, valid and sensitive to the severity of the condition. The instrument can be recommended to researchers and clinicians for the comprehensive assessment of symptoms and their impact on HRQoL on patients with suspected UAB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Bristol Urological Institute, Southmead Hospital, Bristol, UK.
- School of Health and Social Wellbeing, College of Health, Science and Society, University of the West of England, Bristol, UK.
- Patient-Centered Research, Evidera, Wilmington, North Carolina, USA.
- Astellas Pharma Europe B.V., Leiden, The Netherlands.
Förderung
- This study was funded by Astellas Pharma Europe.
- Astellas Pharma Europe
Zitieren
APA
Uren, A., Cotterill, N., Bacci, E. D., Coyne, K., Hakimi, Z., Doyle, S., Atzinger, C., van Till, J. W. O., & Abrams, P. (2025). Psychometric Validation and Scale Derivation of the ICIQ‐Underactive Bladder Patient Reported Outcome Measure. Neurourology and Urodynamics, 44(5), 1099-1108. https://doi.org/10.1002/nau.70065
Vancouver
Uren A, Cotterill N, Bacci ED, Coyne K, Hakimi Z, Doyle S, et al. Psychometric Validation and Scale Derivation of the ICIQ‐Underactive Bladder Patient Reported Outcome Measure. Neurourology and Urodynamics. 2025;44(5):1099-1108. doi:10.1002/nau.70065
BibTeX
@article{Uren2025,
author = {Uren, Alan and Cotterill, Nikki and Bacci, Elizabeth D and Coyne, Karin and Hakimi, Zalmai and Doyle, Scott and Atzinger, Christopher and van Till, J W Olivier and Abrams, Paul},
title = {Psychometric Validation and Scale Derivation of the ICIQ‐Underactive Bladder Patient Reported Outcome Measure},
journal = {Neurourology and Urodynamics},
year = {2025},
volume = {44},
number = {5},
pages = {1099--1108},
doi = {10.1002/nau.70065}
}
EUVIMED